Zhongdong Zhao

This inventor holds 32 USPTO granted patents and 10 published patent applications, plus 8 CIPO patents and 16 EPO patents, primarily in Syk Inhibitors. Top assignees: Gilead Sciences, Inc., Gilead Connecticut, Inc., Genentech, Inc.. Active years: 2011-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zhongdong Zhao. Retrieved from https://idiyas.com/inventor/zhongdong-zhao

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 32 (Patent Applications = 10)

% Patents Active = 87.5

CIPO Patents = 8 (Patent Applications = 3)

EPO Patents = 16 (Patent Applications = 20)

Average Co-Inventor Count = 12.6

ph-index = 10

Forward Citations = 258(Granted Patents)

Location History:

Guilford, CT (US) (2011 - 2019)
Bellevue, WA (US) (2017 - 2024)

Company Filing History:

15 out of 946

Gilead Sciences, Inc.

patents

11 out of 30

Gilead Connecticut, Inc.

Cgi Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2011-2025

Loading Chart...

Areas of Expertise:

Syk Inhibitors

Quinoline Derivatives

Imidazopyridines

Integrin Inhibition

Pyridone Compounds

Tank-Binding Kinase

Substituted Amides

Crystalline Salts

Imidazopyrazines

Aza-Pyridone Compounds

Pyridazinones

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12263163 - Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor (2025-04-01),

2. 12053462 - Quinoline derivatives (2024-08-06),

3. 11578069 - Compounds for inhibition of α4 β7 integrin (2023-02-14),

4. 11517570 - Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine (2022-12-06),

5. 11224600 - Compounds for inhibition of alpha 4 beta 7 integrin (2022-01-18),

6. 11179383 - Compounds for inhibition of α4β7 integrin (2021-11-23),

7. 11174256 - Imidazopyridine derivatives (2021-11-16),

8. 11116760 - Quinoline derivatives (2021-09-14),

9. 10842803 - Imidazopyridines Syk inhibitors (2020-11-24),

10. 10828299 - Crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine (2020-11-10),

11. 10344040 - Pyridone and aza-pyridone compounds and methods of use (2019-07-09),

12. 10342794 - Substituted imidazo[1,2-a]pyrazines as Syk inhibitors (2019-07-09),

13. 10253019 - Tank-binding kinase inhibitor compounds (2019-04-09),

14. 10092583 - Imidazopyridines Syk inhibitors (2018-10-09),

15. 10053469 - Pyridone and aza-pyridone compounds and methods of use (2018-08-21),

Certainly! Here is an article about inventor Zhongdong Zhao.

Title: Zhongdong Zhao: Pioneering Innovations in Pharmaceutical Compounds

Introduction:

In the realm of inventors driving breakthroughs in pharmaceutical compounds, Zhongdong Zhao stands as a notable figure. Hailing from Guilford, CT (US), Zhao's contributions have left a lasting impact on the field of medicine and therapy.

Latest Patents:

1. Compounds for Inhibition of α4 β7 Integrin: Zhao's patented compound of Formula (I) showcases his dedication to developing pharmaceutical compositions for treating inflammatory diseases effectively.

2. Crystalline Succinate Salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine: This patent highlights Zhao's innovative approach as he explores Syk inhibitors for treating conditions like cancer and inflammatory ailments.

Career Highlights:

With an impressive portfolio of 30 patents, Zhao has demonstrated a consistent commitment to driving innovation in the pharmaceutical industry. His work reflects a deep understanding of molecular structures and their therapeutic applications.

Collaborations:

Throughout his career, Zhao has collaborated with esteemed professionals in the field. Noteworthy coworkers include Kevin S Currie and Peter A Blomgren. His tenure at Gilead Sciences, Inc. and Gilead Connecticut, Inc. exemplifies his dedication to advancing pharmaceutical research.

Conclusion:

In conclusion, Zhongdong Zhao's inventive spirit and strategic approach to developing pharmaceutical compounds underscore his position as a key player in the industry. His patents and collaborations attest to his significant contributions towards enhancing therapeutic interventions and improving healthcare outcomes.

Profile summary based on public USPTO records.